Skip to main content
main-content

01.12.2017 | Research article | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding

Zeitschrift:
BMC Cancer > Ausgabe 1/2017
Autoren:
Edita Baltruskeviciene, Diana Schveigert, Vaidotas Stankevicius, Ugnius Mickys, Tadas Zvirblis, Jaroslav Bublevic, Kestutis Suziedelis, Eduardas Aleknavicius
Wichtige Hinweise

Electronic supplementary material

The online version of this article (10.​1186/​s12885-017-3575-z) contains supplementary material, which is available to authorized users.
Abbreviations
CRC
Colorectal cancer
EMT
Epithelial-mesenchymal transition
miRNA, miR
micro RNA
OS
Overall survival
PFS
Progression free survival

Background

Colorectal cancer (CRC) is one of the most frequently occurring cancers worldwide, accounting for 1.2 million new diagnoses and 600.000 deaths every year [ 1]. There is a tendency of decreasing morbidity and mortality, which could be associated with the development of new effective anticancer agents and cancer prophylactics. Identification of novel biomarkers, based on molecular changes caused by the disease, could help to improve those results. In combination with pathological and clinical evaluation, recent biomarker investigations involve genomic, proteomic and transcriptomic research.
Currently, prognosis and treatment choice is based mainly on the information regarding tumor stage. Only a few tumor markers (RAS and BRAF mutation, mismatch repair status) have been implemented into clinical practice [ 2, 3]. Recent evidence suggests, that tumor budding, described as the presence of individual cells and small clusters of tumor cells at the invasive front of the carcinoma, could serve as an additional prognostic factor in stage II CRC [ 4, 5], but there is little information regarding its significance in the advanced disease. The down-regulation of epithelial and the up-regulation of mesenchymal markers suggests that tumor budding is a morphological expression of epithelial mesenchymal transition (EMT), which is associated with tumor invasiveness, formation of metastases and resistance to chemotherapy [ 6, 7].
MicroRNAs (miRNAs) are a class of small (18–25 nucleotides in length), single-stranded noncoding RNAs. They negatively regulate the expression of target genes by binding to 3‘UTR segments of messenger RNAs and are aberrantly expressed in most human cancers, including CRC, in which they may function as tumor suppressors or as oncogenes [ 8]. This posttranscriptional regulation plays a crucial role in controlling key signaling pathways of CRC (RAS/RAF/MAPK, AKT/MTOR and others), though miRNAs are actively involved in proliferation, invasion, angiogenesis, apoptosis and other biological processes [ 810].
Studies examining miRNA expression in CRC have consistently reported the dysregulated expression of nearly 100 miRNAs, compared to non cancerous tissue. Among these, miRNA-143, miRNA-145, let-7, miRNA-148a, miRNA-20a, miRNA-21, miRNA-106, miRNA-155, and miRNA-203 in CRC were among the most frequently mentioned in the literature [ 1114]. The expression of miRNAs in CRC tissue and blood samples could have a prognostic and predictive value [ 11, 15]. Also, an association between miRNA signature and metastases was reported [ 16].
We have focused on miRNA-148a and miRNA-625-3p because of the growing evidence of their importance in carcinogenesis, invasion and progression of CRC and because both of these miRNAs are associated with resistance to oxaliplatin based regimens [ 1719]. Recent data shows that these miRNAs potentially regulate EMT through their targets such as MET/SNAIL, WNT signaling pathways, E-cadherin, N-cadherin, fibronectin and others [ 2022].

Methods

Patients

Fifty-four patients with first-time diagnosed metastatic colorectal cancer participated in a prospective observational study conducted in the National Cancer Institute (Lithuania) in 2011–2014. The median age was 63 years (range 44–76). The male-female gender ratio of the group was 52% and 48%, respectively. 64% of the tumors were located in the colon and 36% in the rectum. The histological tumor type in 80% of the cases was adenocarcinoma, and in 20% – mucinous adenocarcinoma. 98% of the tumors were medium grade. All the patients had metastases in the liver, and for 38% of the patients it was the only site where metastases were detected. In 91% of the cases, the primary tumor was removed before starting chemotherapy. 25% of the patients had undergone resection or radiofrequency ablation of liver metastases and it was performed after 2 months of chemotherapy. The patients received FOLFOX4 chemotherapy with or without Bevacizumab until disease progression or an unacceptable toxicity, according to the institutional guidelines. The median number of chemotherapy cycles was 8. Bevacizumab was administered to 53% of the patients. Treatment efficacy was evaluated every 2 months by a CT (computer tomography) scan according to RECIST 1.1 criteria. After completing the treatment, patients were followed up for progression or survival every 3 months.
The study has been approved by the Regional Biomedical Research Ethics Committee and performed in accordance with the Helsinki declaration. All patients signed the informed consent form before entering the study. Tumor samples were analyzed in the National Pathology Center (Lithuania) and the Scientific Research Center of the National Cancer Institute (Lithuania), and testers were blinded to treatment allocation and outcomes.

Pathology examination

A routine pathology examination, including KRAS testing, was performed. Additionally, samples were evaluated for tumor budding. All the pathology testing was performed by blinded pathologist before starting the treatment under study.

Tumor budding examination

Optimal tumor block for tumor budding evaluation was selected after reviewing H&E stained slides. Then H&E and pan-cytokeratin AE1/AE3 stained sections were assessed using the 10-HPF method. Areas of highest budding density were identified at low power field (×4-×10) and then tumor buds were counted under high magnification (×40). The cut-off value for determining a high degree of budding was considered 10 budding cells per high power field [ 23].

MiRNA extraction and analysis

Formalin-fixed paraffin embedded tissue samples of primary tumors (ensuring the presence of at least 50% of tumour cells in the tumor) and adjacent normal mucosa were prepared by the pathologist. 4–5 sections of 5 μm thickness were obtained and processed for MiRNAanalysis. MiRNA from the samples was extracted using “miRNeasy FFPE Kit” (QIAGEN, Germany). The concentration of miRNA was measured by “NanoDrop2000C” spectrophotometer (Thermo Fisher Scientific,USA). MiRNA expression analysis was done by the RT-PCR method using “TaqMan® MicroRNA Reverse Transkription Kit” (Life Technologies, USA) and “TaqMan® Universal Master Mix II, no UNG” (Life technologies, USA). Each sample was examined in triplicate. Changes in miRNA expression were calculated using the 2 -ΔΔCtmethod.

Bioinformatics

In silico miRNR target analysis was performed using microT-CDS algorithm and miRTarBase to extract theoretically predicted and experimentally validated target-genes, respectively [ 24, 25]. KEGG pathway enrichment analysis of obtained miRNA targets was completed using WebGestalt online tool kit ( http://​www.​webgestalt.​org/​option.​php) as described previously [ 26]. P values were evaluated using Hypergeometric distribution and adjusted with Benjamini and Hochberg post-hoc test. Genes involved in epithelial-mesenchymal transition (EMT) were retrieved form dbEMT database. Genes potentially regulated by miR-148a were further visualized using Cytoscape ver. 3.4.0.

Statistical analysis

Descriptive statistics were used to describe demographic characteristics. The non-parametric Wilcoxon test was used to evaluate the differences between the two data sets. The differences between the two qualitative data groups were evaluated by the Chi-square test. Risk factors for PFS and OS were assessed by Cox regression analysis. Survival trends were evaluated by the Kaplan-Meier method. A log-rank test was used to evaluate the difference between Kaplan-Meier curves. Progression free survival (PFS) was calculated as the timespan from the first day of treatment to the first date of disease progression, the day of a confirmed new tumor or death. Overall survival (OS) was calculated as the time from the first day of treatment to death. If during the last visit to the clinician there was no evidence of disease progression or a new tumor, the date was confirmed as censored. A two-tailed p-value less than 0.05 was considered to be significant. Statistical analysis was performed using the Statistical Analysis System (SAS) package version 9.2.

Results

Both miRNA-148a and miRNA-625-3p were down-regulated in the tumors compared to normal adjacent mucosa. The median values of miRNA-148a were 0.527 (range 0.005–4.485) and 2.94 (range 1.826–4.091) respectively, p < 0.001, and for miRNA-625-3p – 0.492 (range 0.021–4.289) and 5.584 (4.595–6.314) respectively, p < 0.001 (Fig. 1). The patients were divided into high and low expression groups based on the median value. There were no significant differences in the groups according to the age, gender, number and location of metastases or KRAS mutations (Table 1). A significantly higher number of tumors in the colon had a higher expression of miRNA-625-3p ( p = 0.024), but there were no association between miRNA-148a expression and tumor location. There was a trend toward lower miRNA-148a and miRNA-625-3p expression in tumors with a budding phenomenon (both p = 0.051).
Table 1
The association of miRNA-148a, miRNA-625-3p and tumor budding with clinical and pathological characteristics
Characteristic
N
miRNA 148-a expression
miRNA 625-3p expression
Tumor budding
   
Low
High
p
Low
High
p
Yes
No
p
Total
54
27
27
 
27
27
 
21
33
 
Age
 < 65
28
17
12
0.172
15
13
0.586
14
15
0.128
 ≥ 65
26
10
15
12
14
7
18
Gender
 Female
26
13
13
1.000
13
13
1.000
12
14
0.291
 Male
28
14
14
14
14
9
19
Location
 C18–19
34
15
19
0.260
13
21
0.024
11
23
0.199
 C20
20
12
8
14
6
10
10
Side
 Right
12
6
6
1.000
5
7
0.513
7
5
0.117
 Left
42
21
21
22
20
14
28
T
 1–3
36
17
19
0.564
16
20
0.248
14
22
1.000
 4
18
10
8
11
7
7
11
N
 0–1
34
15
19
0.260
16
18
0.573
11
23
0.199
 2
20
12
8
11
9
10
10
Extrahepatic metastases
 Yes
33
15
19
0.260
15
18
0.402
14
19
0.402
 No
21
12
8
12
9
7
14
Number of metastatic sites
 1–2
39
20
19
0.762
22
17
0.129
15
24
0.917
 ≥ 3
15
7
8
5
10
6
9
Type of adenocarcinoma
 Adenocarcinoma
43
24
19
0.091
24
19
0.311
18
25
0.376
 Mucinous
11
3
8
4
7
3
8
Tumor budding
 Yes
21
14
7
0.051
14
7
0.051
-
-
-
 No
33
13
20
13
20
-
-
KRAS
 Mutated
37
18
19
0.770
17
20
0.379
15
22
0.713
 Wild type
17
9
8
10
7
6
11
Further analysis revealed a significantly lower expression of both miRNAs in tumors with budding phenomenon compared to tumors without it (median values of miRNA-148awere 0.314 and 0.753 respectively, p = 0.011; and of miRNA-625-3p  were 0.404 and 0.620 respectively, p = 0.0360 (Fig. 2a and b). A lower expression of both miRNAs was also noticed in tumors of the rectum, compared to tumors in the colon (median values of miRNA-148a were 0.412 and 0.624 respectively, p = 0.098; and of miRNA-625-3p were 0.390 and 0.665 respectively, p = 0.037). The difference was significant only for miRNA-625-3p (Fig. 2c and d).
Based on treatment response, patients were divided into 2 groups: responders (complete and partial response; 32 patients, 58%), and non-responders (stable and progressive disease; 23 patients, 42%). There were no differences in response rates regarding miRNA-148a or miRNA-625-3p expression.
The median follow up was 16 months (range 3–51) for all patients. Progression free survival (PFS) was 6 (95% CI: 5–7) and 9 (95% CI: 6–12) months in patients with high and low miRNA-148a expression respectively ( p = 0.033); and 6 (95% CI: 5–7) and 9 (95% CI: 6–12) months in patients with high and low miRNA-625-3p expression respectively ( p = 0.357) (Fig. 3a and b).
The overall survival (OS) was 18 (95% CI: 12–24) and 24 (95% CI: 18–30) months in patients with high and low miRNA-148a expression respectively ( p = 0.199); and 18 (95% CI: 12–24) and 24 (95% CI: 18–30) months in patients with high and low miRNA-625-3p expression, respectively ( p = 0.361) (Fig. 3c and d).
The Univariate Cox regression analysis revealed that a higher expression of miRNA-148a was associated with a shorter PFS. No other significant factors were found in this analysis.
Budding phenomenon was detected in 39% of cases. There were no significant differences in the groups with budding compared to no budding and age, sex, location of the tumor, size, lymph node involvement, histological type, metastases or KRAS mutation (Table 1). In further analysis, the budding status did not influence PFS – 7 (95% CI: 5–9) and 8 (95% CI: 5–11) months respectively ( p = 0.499); or OS – 18 (95% CI: 5–31) and 18 (95% CI: 7–29) month respectively ( p = 0.709).
Inorder to elucidate the biological processes which could be potentially regulated by miR-148a and miR-625-3p, miRNA target analysis was performed. The analysis identified 502 and 98 genes theoretically predicted as miR-148a and miR-625-3p targets (Fig. 4a). However, only 11 of them were determined as regulated in common between the semiRNAs (Fig. 4b). In addition, the analysis revealed that 29 target genes were associated with miR-148a with high experimental confidence. Further, to investigate any relations between miR-148a/miR-625-3p and epithelial-mesenchymal transition (EMT), the list of all known EMT genes retrieved from dbEMT was compared with the list of obtained target genes. Venn diagram analysis indicated that 13 and 6 EMT genes could be potentially regulated by miR-148a and miR-625-3p, respectively (Fig. 4c). Interestingly, among them key players of EMT ZEB1 and TGFB2 were predicted targets of miR-148a, and TGFBR1 – miR-625-3p. The list of EMT genes potentially regulated by these two miRNAs is depicted in Additional file 1: Table S1. Next, KEGG pathway enrichment analysis indicated 7 KEGG categories enrichedin miR-148a target-genes (Additional file 2: Table S2). Among them FoxO ( p = 0.012) and PI3K-Akt ( p = 0.0187) signaling pathways were the most significantly enriched functional categories. Inaddition, the pathway enrichment data revealed that categories associated with cell adhession including focal adhesion, regulation of actin cytoskeleton and ECM-receptor interaction were significantly enriched in miR-148a target-genes. miR-148a and target gene networks related to FoxO/PI3K-Akt (27 target-genes) and cell adhesion (21 target-genes) functional groups are visualized in Fig. 4d. However, KEGG analysis did not obtain any significant pathway enrichment of miR-625-3p target-genes (data is not shonwn).

Discussion

Multiple data affirm that miRNAs are involved in mechanisms of excessive growth, resistance to apoptosis, angiogenesis, invasion, and metastasis [ 27, 28]. In this study, we have investigated miRNA-148a and miRNA-625-3p expression, due to the growing evidence of their importance in carcinogenesis and progression of CRC as well as in prediction of treatment efficacy.
MiRNA-148a down-regulation has been detected in gastric, breast, non-small cell lung cancer and other tumors [ 20, 29, 30] compared to normal tissues. Several trials reported down-regulation of miRNA-148a in CRC cells and it’s association with more advanced disease and poor prognosis [ 18, 3133].
Y. Hibino et al. [ 31] showed significant downregulation of miRNA-148a expression in CRC and adenoma compared to normal colonic mucosa. MiRNA-148a expression was significantly lower in high-grade adenoma compared to low grade ( p = 0.005). In more advanced CRC casesit differed depending on pT ( p = 0.010), pN ( p = 0.007) and stage ( p = 0.027). Furthermore, a low miRNA-148a expression was an independent prognostic factor of OS for stage III patients (HR 4.421, 95% CI 1.473–18.428, p = 0.006).
H. L. Tsai et al. [ 32] found a relationship between early relapse of CRC patients in the II and III stages that underwent curative resection and low miRNA-148a expression in the tumor (OR 5.221; 95% CI, 2.068–13.174, p < 0.0001) and serum ( p = 0.045). Lower miRNA-148a expression in the tumor was also associated with shorter DFS ( p = 0.0006) and a worse OS ( p = 0.0156). Investigators demonstrated that miRNA-148a inhibits cell proliferation (possibly through the mechanism of arresting the cell cycle during phase 2) and migration.
M. Takahashi et al. [ 18] reported that low miRNA-148a expression is associated with advanced CRC stages (III/IV versus normal mucosa, p < 0.0001) and is an independent prognostic factor of PFS for stage III patients (HR 1.83, 95% CI 1.12–2.99, p = 0.017) and OS for stage IV patients (HR 1.93, 95% CI 1.15–3.23, p = 0.014). In addition, they reported that miRNA-148a expression may be regulated by promoter methylation, and that there is an independent association between miRNA-148a methylation and poor survival of stage IV CRC patients.
H. Huang et al. [ 34] reported that MiRNA-148a negatively regulates the expression of MMP7, which is involved in tumor cell invasion and associated with advanced stages and poor clinical outcome of CRC.
H. Zhang et al. [ 35], however, did not show any significant differences between miRNA-148a expression in tumor and normal tissue, as well as no correlation with patients’ clinical and pathological characteristics. It was confirmed that BCL-2 is a target of miRNA-148a, revealing its proapoptotic potential.
Also there is evidence regarding the importance in cancer development of other targets of miRNA-148a, such as DNMT1 – inhibition of which increases expression of multiple genes by epigenetic changes (reduced methylation) [ 36]; ERBB3 – involved in angiogenesis [ 37]; CDC25B – cell cycle regulator [ 38]; and IGF-IR, AKT, MAPK/ERK – cell growth [ 39]. By silencing these and potentially other target genes, miRNA-148a inhibits cell growth, proliferation, angiogenesis, invasion, andsusceptibility to apoptosis.
In the present study, we determined the deregulation of miRNA-148a in tumor tissue, compared to normal colonic mucosa. There was a trend toward higher miRNA-148a expression in mucinous adenocarcinoma compared to adenocarcinoma ( p = 0.068), but there were no associations with other major clinical and pathological features (such as age, gender, tumor location and size, lymph node involvement, number or site of metastases, KRAS mutation status). These findings correspond to the results of the H. Zhang study [ 35], but in both studies, the results might have been influenced by the small sample size.
In our study, miRNA-148a expression was lower in cancers with tumor budding (median values accordingly 0.314 and 0.753, p = 0.011), which has been found by other studies to be associated with a more invasive phenotype and distant metastases [ 40] and determined as prognostic factor independent from CRC stage [ 3, 4].
Tumor budding indicates the presence of individual cells and small clusters of tumor cells at the invasive front of the carcinoma and is thought to represent epithelial-mesenchymal transition (EMT) [ 3, 4]. EMT is mainly regulated by SNAIL, TWIST and ZEB transcription factors and characterized by down-regulation of epithelial markers (E-cadherin, claudin etc.) and up-regulation of mesenchymal markers (Fibronectin, N-cadherin, MMPs etc.) [ 40]. The correlation between EMT and tumor budding is based on similarities in characteristics – low membranous level of E-cadherin [ 41], upregulation of fibronectin and vimetin [ 42], activation of TGF-β [ 43] and other pathways [ 7].
Studies demonstrated that miRNA-148a suppresses EMT and the expression of several genes overexpressed in EMT [ 20, 21]. J.P. Zhang et al. [ 21] reported that miR-148a may promote the expression of an epithelial marker (E-cadherin), reduce the levels of mesenchymal markers (N-cadherin, fibronectin or vimentin), and negatively regulate MET/SNAIL signaling and in turn inhibit the EMT and metastasis of hepatoma cells. Z. Qin et al. [ 22] recently suggested that miR-148a, miR-505 and miR-1207-5p might be induced by growth factors, and function as EMT and metastasis inhibitors by suppressing key EMT and WNT signaling molecules.
MiRNA-625-3p is another miRNAwith growing evidence of involvement in development and progression of different types of cancer [ 4447]. M. Wang et al. [ 45] have reported that miRNA-625-3p silences the expression of integrin-linked kinase (ILK), the activation of which results in oncogenic transformation to invasive and metastatic phenotypes. In concordance with this, an inverse relationship has been established between downregulated miRNA-625-3p expression in gastric cancer and lymph node metastasis. In recent studies, downregulation of miRNA-625-3p was associated with more advanced Tstages and metastases of esophageal cancer. In addition, it was demonstrated that miRNA-625-3p negatively regulates Sox2, which promotes tumor invasion and metastasis by stimulating EMT via regulation of WNT/β-catenin, and tumor growth via AKT/MTOR signaling pathways [ 45, 47].
The role of miRNA-625-3p in CRC is not well understood. X. Lou et al. [ 46] reported that decreased miRNA-625-3p expression correlated with lymphnode metastasis ( p = 0.038), liver metastasis ( p = 0.031), and was an independent prognostic factor for OS (HR 0.454; CI 95% 0.218–0.943, p = 0.034). H. Zheng et al. [ 48] showed that miRNA-625-3p might positively regulate colorectal cancer cell migration and invasion through the SCAI/E-cadherin/MMP9 pathway. M. H. Rasmussen et al. [ 17] did not ascertain a prognostic significance between miRNA-625-3p expression and CRC stage II-III, but demonstrated that a high level of miRNA-625-3p is associated with shorter OS (HR 1.87, CI 95% 1.2–3.41, p = 0.039) in metastatic CRC.
In our study, we found a significantly lower miRNA-625-3p expression in tumors with budding phenomenon (0.404 and 0.620 respectfully, p = 0.036). This finding indicates potential miRNA-625-3p involvement in EMT, which is also supported by earlier reported data about this miRNAs role in WNT/β-catenin and SCAI/E-cadherin/MMP9 pathways.
Taking in to account the wide spectrum of miRNA targets, they have been actively investigated as potential predictive markers. One of the main chemotherapy agents for treating CRC – oxaliplatin –induces cell apoptosis by causing DNA interstrand cross-links, [ 49]. Bcl2 as target of miRNA-148a provides the rationale for using miRNA-148aas a predictive marker of the response to oxaliplatin. M. Takahashi et al. [ 18] reported a significant association between low miRNA-148a expression and a worse response to oxaliplatin-based therapy ( p = 0.006), a worse OS (median 16.1 vs. 25.6 month, p = 0.024), and a trend toward a worse PFS (median 8.1 vs. 10.1 month, p = 0.16) in metastatic CRC patients. In contrast, J.B. Kjersem et al. [ 11] reported an association between high miRNA-148a expression in the plasma of metastatic CRC patients receiving oxaliplatin-based chemotherapy and a decrease in PFS (HR 1.3; 95% CI 1.1–1.6, p = 0.007). M. H. Rasmussen et al. [ 19] have reported that high miRNA-625-3p expression is a negative predictive factor for response to first line oxaliplatin-based chemotherapy in metastatic CRC (OR 6.25, 95% CI 1.8–21.0). Current evidence suggests that the investigation of both miRNAs mentioned, could be beneficial in predicting the efficacy of oxaliplatin. Our results did not confirm this statement – neither miRNA-148a expression nor miRNA-625-3p expression was associated with response rates in studied patients. High miRNA-148a expression was associated with worse PFS (6 month and 9 month respectively, p = 0.033), but not OS (18 month and 24 month respectively, p = 0.199). MiRNA-625-3p did not influence PFS or OS. Small sample size of the study limited the statistical power to identify differences in PFS and OS.
To our knowledge, our study is the first that determined an association between low miRNA-148a and miRNA-625-3p expression and tumor budding. The small sample size is the major limitation of our study and our findings need to be validated in an independent cohort. However, our results allow us to propose an interesting hypothesis regarding the possible role of the tested RNAs in the tumor budding process which is likely associated with EMT.
Our bioinformatics analysis revealed that 19 EMT related genes including key regulators of EMT – ZEB1, TGFB2 and TGFBR1 – are potential target genesof miRNA-148a and miRNA-625-3p, supporting the roles of these miRNAs as regulators of EMT. In addition, our results are consistent with published data, regarding the role of miRNA-148a and miRNA-625-3p in EMT regulation.

Conclusions

The presented study has identified a significant relationship between low miRNA-148a and miRNA-625-3p expression and tumor budding, which is thought to represent EMT. The results show that the studied miRNAs may be associated with a more aggressive phenotype and could be the potential prognostic and predictive biomarkers in CRC. Further investigation is needed to confirm the involvement these miRNAs in EMT, and their prognostic and predictive value.

Acknowledgements

None.

Funding

National Cancer Institute covered the cost of study organization and article publication.

Availability of data and materials

Clinical data of study participants obtained in this study except the personal data is available on request addressed to corresponding author.

Ethics approval and consent to participate

The study (No. 158200–06–347-88) has been approved by Vilnius Regional Biomedical Research Ethics Committee (Vilnius). All participants of the study have signed the informed consent to participate before study specific procedures have been started.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise